All 9 /Events 0 /In The News 8 /Press Releases 1

NRG raises $67M to test mitochondrial pore inhibitor in ALS

BioWorld

Read more
(behind a paywall)
8 September 2025/by Webadm

A UK biotech takes aim at Parkinson’s, ALS by drugging mitochondria

Biopharma Dive

Read more
8 September 2025/by Webadm

UK’s NRG Powers Up With £50m For Promising Mitochondrial Therapy

SCRIP

Read more
(behind a paywall)
8 September 2025/by Webadm

NRG raises $67 million for a small molecule for Parkinson’s and ALS

c&en

Read more
8 September 2025/by Webadm

Stevenage, UK based NRG Therapeutics raised a $67M series B today to advance its aim to restore mitochondrial function and slow the progression of neurodegenerative diseases like Parkinson’s and ALS

Biotech TV

Watch more
8 September 2025/by Webadm

A British mitochondrial startup wants to break ground in ALS and Parkinson’s. It has £50M to try

Endpoints News

Read more
8 September 2025/by Webadm

NRG Therapeutics Announces Oversubscribed £50m ($67m) Series B Financing to Deliver Clinical Data in Parkinson’s and Proof of Concept in ALS/MND

Oversubscribed £50m Series B led by SV Health Investors’…
8 September 2025/by Webadm

Mitochondria: Movers and Shakers – a podcast about life with Parkinson’s

Apple Podcasts

Listen more
8 March 2025/by Webadm

Novel Parkinson’s therapy protects mitochondrial function

Drug Discovery World

Read more
5 November 2024/by Webadm

Michael J Fox Foundation adviser joins NRG Therapeutics

Business Weekly Read more

NRG Therapeutics expands team with CDO appointment

thepharmaletter Read  more

NRG Therapeutics Announces Further Expansion with the Appointment of Paul Thompson as Chief Development Officer

Stevenage, UK, 1 December 2025 - NRG Therapeutics Ltd. (“NRG”),…

NRG Therapeutics appoints Paul Thompson as CDO

Drug Discovery World Read more

UK Life Sciences Future50 – Momentum in an evolving landscape

pwc Read more (pdf)

11 neuroscience biotech companies you should know about

Labiotech Read more

NRG Therapeutics Announces Senior Appointments as it Advances NRG5051 Towards First-in-Human Clinical Studies

Stevenage, UK, 23 October 2025 - NRG Therapeutics Ltd. (“NRG”),…

Is this mitochondria’s big moment?

Longevity Technology Read more

Biotechs, BIA, patient charities and investors: the power of relationships

BIA, UK BioIndustry Association Read more